Pain. Other and unspecified general anaesthetics
Conditions
Interventions
Intervention 1: An 18-gauge intravenous catheter will be inserted for all patients in the dorsum of the hand. One minute prior to Propofol injection, all patients will be received the study drug throu
production series 11-207). Next, 2.5 mg/kg of Propofol 2% (Melsugen, Germany
production series- 34209) will be administered at a rate of i 1 ml/s. Verbal Rating Scale (VRS) will be used to assess the severity of pain during injection. Intervention 2: An 18-gauge intravenous ca
production series 1228054891). Next, 2.5 mg/kg of Propofol 2% (Melsugen, Germany
production series- 34209) will be administered at a rate of i 1 ml/s. Verbal Rating Scale (VRS) will be used to assess the severity of pain during injection. Intervention 3: An 18-gauge intravenous ca
production series -207) at a rate of 1 mg/s. Next, 2.5 mg/kg of Propofol 2% (Melsugen, Germany
production series- 34209) will be administered at a rate of i 1 ml/s. Verbal Rating Scale (VRS) will be used to assess the severity of pain during injection.
Treatment - Drugs
An 18-gauge intravenous catheter will be inserted for all patients in the dorsum of the hand. One minute prior to Propofol injection, all patients will be received the study drug through a 5 ml syring
production series- 34209) will be administered at a rate of i 1 ml/s. Verbal Rating Scale (VRS) will be used to assess the severity of pain during injection
Sponsors
Vice Chancellor for research Mazandaran University of Medical Sciences.
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria ; class I and II ASA Exclusion criteria; patients with high intracranial pressure, unstable hemodynamics, severe mental disorders, history of allergy to drugs used, kidney, liver or heart dysfunction, addiction and use of Calcium or Magnesium blockers
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Propofol injection pain. Timepoint: Once. Method of measurement: Verbal Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: For 1 hours. Method of measurement: Surveillance the patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAttieh Nikkhah
Mazandaran University of Medical Sciences
Outcome results
None listed